Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients
- 11 September 2004
- Vol. 22, S44-S48
- https://doi.org/10.1016/j.vaccine.2004.08.016
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003American Journal of Infection Control, 2003
- Lung Infections Associated with Cystic FibrosisClinical Microbiology Reviews, 2002
- Pseudomonas Vaccination and ImmunotherapyJournal of Burn Care & Rehabilitation, 2001
- Human Monoclonal Antibodies againstPseudomonas aeruginosaLipopolysaccharide Derived from Transgenic Mice Containing Megabase Human Immunoglobulin Loci Are Opsonic and Protective against Fatal Pseudomonas SepsisInfection and Immunity, 2001
- Generation and Characterization of a Human Monoclonal IgM Antibody That Recognizes a Conserved Epitope Shared by Lipopolysaccharides of Different Gram-Negative BacteriaHybridoma, 1996
- Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosisThe Journal of Pediatrics, 1995
- Affinities of endotoxin-specific human monoclonal antibodies, their polyclonal counterparts and murine monoclonal antibodiesResearch in Immunology, 1993
- Affinity Constants of Naturally Acquired and Vaccine-Induced Anti-Pseudomonas aeruginosa Antibodies in Healthy Adults and Cystic Fibrosis PatientsThe Journal of Infectious Diseases, 1992
- Biological Role of Different Antibody ClassesInternational Archives of Allergy and Immunology, 1989
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975